NEO212 is an orally active, blood-brain barrier permeable conjugate of Temozolomide (TMZ) (HY-17364) and Perillyl Alcohol (POH) (HY-N7000), with potent anticancer activity. NEO212 overcomes classical TMZ resistance and DNA alkylation by depleting MGMT. By inhibiting the FAK/Src signaling pathway, NEO212 reduces the production of MMP2 and MMP9, induces mesenchymal-epithelial transition, and inhibits the migration, invasion and tumor progression of glioma stem cells. NEO212 disrupts autophagy flux to enhance mitochondrial apoptosis, it induces differentiation of acute myeloid leukemia (AML) cells into macrophages and proliferation arrest[1][2][3][4].
Molekulargewicht:
372.39
CAS Nummer:
[1361198-79-9]
Formel:
C17H20N6O4
Target-Kategorie:
Apoptosis,Autophagy,DNA/RNA Synthesis,FAK,MMP,Src
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
